Pharmacokinetics of clozapine and risperidone: A review of recent literature

Journal of Clinical Psychopharmacology

Volumn 16, Issue 2, 1996, Pages 177-187

  Byerly, Matthew J ^a   DeVane, C Lindsay ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450; DRUG METABOLITE; RISPERIDONE;

DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; STEADY STATE;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; METABOLIC CLEARANCE RATE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0009404019     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199604000-00010     Document Type: Review

References (78)

1. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, Ltd, 1992: 241-51.
2. Van Tol HHM, Bunzow JR, Guan H-C, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-4.
3. Meltzer HY, Matsubara S, Lee J-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251: 238-46.
4. Lieberman J, Saltz B, Johns C, Pollack S, Borenstein M, Kane J. The effect of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158:503-10.
5. Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:489-96.
6. Safferman A, Lieberman J, Kane J, Szymanski S, Kinon B. Update on clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-62.
7. Meltzer H, Goode D, Schyve P, Young M, Fang V. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136:1550-5.
8. Claghorn J, Honigfeld G, Abuzzahab F. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-84.
9. Meltzer H, Bastani B, Young-Kwon K, Ramirez L, Burnett S, Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology (Berl) 1989;99 [suppl]:68-72.
10. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berl) 1989;99 [suppl]:118-21.
11. Wilson WH, Claussen AM. Seizures associated with clozapine treatment in a state hospital. J Clin Psychiatry 1994;55:184-8.
12. Hollister LE, New psychotherapeutic drugs. J Clin Psychopharmacol 1994;14:50-63.
13. Jann M, Grimsley S, Gray E, Chang W. Pharmacokinetics and pharmcodynamics of clozapine. Clin Pharmacokinet 1993;24:161-76.
14. Fitton A, Heel R. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia Drugs 1990;40:722-47.
15. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R, The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55[suppl5]:13-7.
16. Cheng Y, Lundberg T, Bondesson U, Lindstrom L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988;34:445-9.
17. Choc M, Hsuan F, Honigfeld G, Robinson W, Ereshefsky L, Crismon M, Saklad S, Hirschowitz J, Wagner R. Single- vs. multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990;4:347-51.
18. Sayers A, Amsler H. Clozapine. In: Goldberg M, ed. Pharmacological, biochemical properties of drug substances. Washington, DC: American Pharmaceutical Association and Academy of Pharmaceutical Sciences, 1977:1-31.
19. Ackenheil M, Clozapine - pharmacokinetic investigations, biochemical effects in man. Psychopharmacology (Berl) 1989; 99[suppl]:32-7.
20. Bondesson U, Lindstrom L. Determination of clozapine and its N-desmethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988;95:472-5.
21. Choc M, Lehr R, Hsuan F, Honigfeld G, Smith H, Borison R, Volavka J. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987;4:402-5.
22. Dahl M-L, Llerena A, Bondesson U, Lindstrom L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994;37:71-4.
23. Crismon ML, Ereshefsky L, Saklad S. A comparison of clozapine absorption in the postprandial versus fasting states. Pharm Res 1988;5[suppl]:171.
24. Vanden Bussche G, Heykants J, De Coster R. Pharmacokinetic profile and neuroendocrine effects of the new antipsychotic risperidone. Presented at the 16th Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Munich, West Germany: 1988.
25. Huang M, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen A, Zylicz Z, Visscher H, Jonkman J. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54:257-68.
26. Heykants J. Pharmacokinetics of risperidone [abstract]. Presented at the 1st International Risperidone Investigators Meeting. Paris, France, March 1992.
27. Van Beysterveldt L, Geerts RJF, Leysen J, Megens A, Van den Eynde H, Meuldermans W, Heykants J. The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat, Psychopharmacology (Berl) 1994;114:53-62.
28. Ishigooka J, Wakatabe H, Murasaki M, Miura S. Phase I study of risperidone, an antipsychotic and antagonist of serotonin-S2 and dopamine-D2. Satellite Symposium at the 17th congress of CINP; Risperidone: Major Progress in Antipsychotic Treatment. 1990;38.
29. Hossain M, Ette EI, Ludden TM. Pharmacokinetics of risperidone in extensive and poor metabolizers: the use of mixed effects modeling. J Clin Pharmacol 1994;34:1019.
30. Lin SK, Chang WH, Chung MC, Lam YW, Jann MW. Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 1994;34:318-24.
31. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25.
32. Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55[suppl B]:94-7.
33. Perry P, Miller D, Arndt S, Cadoret R. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-5.
34. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97.
35. Gerson SL, Arce C, Meltzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994;86:555-61.
36. Pirmohamed M, Templeton E, Breckenridge AM, Park BK. In vitro bioactivation of clozapine to a chemically reactive metabolite by human and mouse liver microsomes. Br J Clin Pharmacol 1992;35:168P.
37. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
38. Carrillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304.
39. Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1c receptor antagonists. Eur J Pharmacol 1993;245:179-82.
40. Meltzer H. The mechanism of action of novel atypical antipsychotic drugs, Schizophr Bull 1991;17:262-87.
41. Meltzer H. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer H, ed. Novel antipsychotic drugs. New York: Raven Press, 1992:1-13.
42. Meier J. Bioanalytical assay of clozapine and its N-oxide metabolite and the determination of their blood levels in the dog. Br J Pharmacol 1975;53:440P.
43. Rosenthaler J, Nimmerfall F, Sigrist R, Munzer H. Nonequilibrium method for the radioimmunoassay of clozapine in the presence of metabolites. Eur J Biochem 1977;80:603-9.
44. Luo H, McKay G, Midha KK. Identification of clozapine N-glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol Mass Spectrom 1994;23: 147-8.
45. Ackenheil M, Brau H, Burkart A, Franke A, Pacha W. Antipsychotische wirksamkeit im verhaltins zum plasmaspiegel von clozapin. Arzneimittelforschung 1976;26:1156-8.
46. Haring C, Meise U, Humpel C, Saria A, Fleischhacker W, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacology (Berl) 1989;99[suppl]:38-40.
47. Haring C, Fleischhacker W, Schett P, Humpel C, Barnes C, Sana A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5.
48. Ackenheil M, Beckmann H, Greil W, Hoffmann G, Makianos E, Raese J. Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man. In: Forrest C, Carr J, Usdin E, eds. The phenothiazines and structurally related drugs. New York: Raven Press, 1974:647-57.
49. Van Peer A, Gasparini R, Huang M, Woestenborghs E, Heykants J. Risperidone dose-proportionality in psychotic patients using a population pharmacokinetic analysis. Presented at the Clinical Pharmacological Meeting, Ghent, Belgium, April 1992.
50. Mannens G, Huang M-L, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos Biol Fate Chem 1993;21:1134-41.
51. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology (Berl) 1989;99:445-9.
52. Ereshefsky L, Anderson C, True J, Saklad S, Riesenman C, Toney G, Miller A. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy 1993;13:292.
53. Anderson CB, True JE, Ereshefsky L, Miller AL, Peters BL, Velligan DI. Risperidone dose, plasma levels and response. 146th Meeting of the American Psychiatric Association, San Francisco, May 1993.
54. Inaba T, Jurima M, Mahon W, Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos Biol Fate Chem 1985;13:443-8.
55. Fischer V, Vogels B, Maurer G, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome p450 2D6. J Pharmacol Exp Ther 1992;260:1355-60.
56. Raitasuo V, Lehtovaara R, Huttunen M. Carbamazepine and plasma levels of clozapine. Am J Psychiatry 1993;150:169.
57. Szymanski S, Lieberman A, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21-2.
58. Miller D. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23-5.
59. Tyson SC, DeVane CL, Risch SC. Probable pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995;152:1401-2.
60. Bertilsson L, Carrillo JA, Dahl M-L, Llerena A, Alm C, Bondesson U, Lindstrom L, De La Rubia IR, Ramos S, Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
61. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
62. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995;15:141-3.
63. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
64. Wietholtz H, Zysset T, Kreiten K, Kohl D, Buchsei R, Matern S. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;36:401-6.
65. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer H. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993;13:383-90.
66. Centorrino F, Baldessarini RJ, Kando JK, Frankenburg FR, Volpicelli SA, Puopolo PR, Flood JG. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5.
67. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SZ, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993;9:117-24.
68. Miller D, Fleming F, Holman T, Perry P. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55[suppl B]:117-21.
69. Owen JA, Delva NJ, Lawson JS. Clozapine concentrations and clinical response in schizophrenic patients. Am J Psychiatry 1992; 149:1120-1.
70. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Plon L, Plon H, Park L, Chang Y, Oldroyd J, Cooper T. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55[suppl B]:133-8.
71. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152:179-82.
72. Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman JA, Pollack S, Safferman AZ, Kane JM. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994;55[suppl B]:78-81.
73. Pilowsky LS, Costa DC, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202.
74. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538-44.
75. Farde L, Nordstrom AL, Nyberg S, Halldin C, Sedvall G. D1-, D2-, 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55[suppl B]:67-9.
76. Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW. EEG alterations in patients treated with clozpine in relation to plasma levels. Psychopharmacology (Berl) 1994;114:97-100.
77. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
78. Marder SR, Meibach R. Risperidone in the treatment of schizophrenia Am J Psychiatry 1994;151:825-35.